This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Nintedanib* has been investigated in lung cancer as part of the LUME-Lung clinical trial programme. Within this section you will find an overview of the main trials within this programme as well as links to pages for further information.
Nintedanib clinical trials in thoracic malignancies
The approval of nintedanib for the treatment of adult patients with advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy is based on the Phase III LUME-Lung 1 trial.1
Nintedanib is being investigated in patients with unresectable MPM within the LUME-Meso Phase II/III trial. Based on the Phase II results,2 nintedanib received orphan drug designation for the treatment of malignant pleural mesothelioma (MPM) from the US Food & Drug Administration providing 7-year marketing exclusivity if approved.3,4 The Phase III part of the LUME-Meso trial of nintedanib plus pemetrexed/cisplatin vs placebo plus pemetrexed/cisplatin for the treatment of patients with unresectable MPM is currently recruiting patients with epithelioid histology.5
The following table shows the clinical trials of nintedanib in NSCLC and MPM; you can find links to further information on this site and published papers.
Ongoing clinical trials
DLT, dose-limiting toxicity; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK/PD, pharmacokinetics/pharmacodynamics.
Reck M, et al. Lancet Oncol 2014;15(2):143-55.
Grosso F, et al. J Clin Oncol 2017. In press.
US Food & Drug Administration. Nintedanib orphan drug designation, 12 December 2016. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=547916. Accessed: July 2017.
US Food & Drug Administration. e-CFR 21 PART 316 Orphan Drug & the Orphan Drug Act 1983. https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm124562.htm. Accessed: July 2017.
Scagliotti GV, et al. Clin Lung Cancer 2017; Mar 22. pii: S1525-7304(17)30087-6. [Epub ahead of print]. https://doi.org/10.1016/j.cllc.2017.03.010. Accessed: July 2017.
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications. Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue